Comments
Loading...

Conmed Analyst Ratings

CNMDNYSE
Logo brought to you by Benzinga Data
The dividend Ex-Date is today
Consensus Rating1
Hold
Highest Price Target1
$141.00
Lowest Price Target1
$55.00
Consensus Price Target1
$86.11

Conmed Analyst Ratings and Price Targets | NYSE:CNMD | Benzinga

Conmed Corp has a consensus price target of $86.11 based on the ratings of 9 analysts. The high is $141 issued by Keybanc on July 27, 2023. The low is $55 issued by Stifel on April 28, 2025. The 3 most-recent analyst ratings were released by Needham, JP Morgan, and Wells Fargo on June 12, 2025, May 1, 2025, and May 1, 2025, respectively. With an average price target of $58.67 between Needham, JP Morgan, and Wells Fargo, there's an implied 6.46% upside for Conmed Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
2
2
Feb
0
0
0
0
Apr
1
2
May
0
0
0
0
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.8
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Needham
JP Morgan
Wells Fargo
Stifel
Piper Sandler

1calculated from analyst ratings

Analyst Ratings for Conmed

Buy NowGet Alert
06/12/2025Buy Now10.69%Needham
Mike Matson70%
$61 → $61DowngradeBuy → HoldGet Alert
05/01/2025Buy Now5.25%JP Morgan
Robbie Marcus66%
$70 → $58MaintainsNeutralGet Alert
05/01/2025Buy Now3.44%Wells Fargo
Vik Chopra44%
$70 → $57MaintainsEqual-WeightGet Alert
05/01/2025Buy Now10.69%Needham
Mike Matson70%
$91 → $61MaintainsBuyGet Alert
04/28/2025Buy Now-0.19%Stifel
Rick Wise63%
$75 → $55DowngradeBuy → HoldGet Alert
02/06/2025Buy Now36.1%Stifel
Rick Wise63%
$72 → $75MaintainsBuyGet Alert
02/06/2025Buy Now27.03%Wells Fargo
Vik Chopra44%
$74 → $70MaintainsEqual-WeightGet Alert
02/06/2025Buy Now65.13%Needham
Mike Matson70%
$97 → $91MaintainsBuyGet Alert
02/06/2025Buy Now27.03%JP Morgan
Robbie Marcus66%
$85 → $70DowngradeOverweight → NeutralGet Alert
10/31/2024Buy Now76.02%Needham
Mike Matson70%
$97 → $97ReiteratesBuy → BuyGet Alert
10/04/2024Buy Now76.02%Needham
Mike Matson70%
$97 → $97ReiteratesBuy → BuyGet Alert
08/01/2024Buy Now45.17%Piper Sandler
Matt O'Brien54%
$95 → $80MaintainsOverweightGet Alert
08/01/2024Buy Now37.91%Stifel
Rick Wise63%
$88 → $76MaintainsBuyGet Alert
08/01/2024Buy Now28.84%Wells Fargo
Vik Chopra44%
$77 → $71MaintainsEqual-WeightGet Alert
08/01/2024Buy Now76.02%Needham
Mike Matson70%
$106 → $97MaintainsBuyGet Alert
07/25/2024Buy Now92.35%Needham
Mike Matson70%
$107 → $106MaintainsBuyGet Alert
05/06/2024Buy Now94.17%Needham
Mike Matson70%
$107 → $107ReiteratesBuy → BuyGet Alert
04/25/2024Buy Now36.1%JP Morgan
Robbie Marcus66%
$115 → $75MaintainsOverweightGet Alert
04/25/2024Buy Now39.73%Wells Fargo
Vik Chopra44%
$98 → $77MaintainsEqual-WeightGet Alert
04/25/2024Buy Now72.39%Piper Sandler
Matt O'Brien54%
$100 → $95MaintainsOverweightGet Alert
04/25/2024Buy Now94.17%Needham
Mike Matson70%
$129 → $107MaintainsBuyGet Alert
02/01/2024Buy Now81.47%Piper Sandler
Matt O'Brien54%
$130 → $100MaintainsOverweightGet Alert
02/01/2024Buy Now108.68%JP Morgan
Robbie Marcus66%
$135 → $115MaintainsOverweightGet Alert
02/01/2024Buy Now77.84%Wells Fargo
Durgesh Chopra69%
$107 → $98MaintainsEqual-WeightGet Alert
02/01/2024Buy Now134.09%Needham
Mike Matson70%
$119 → $129MaintainsBuyGet Alert
10/27/2023Buy Now135.9%Piper Sandler
Matt O'Brien54%
$145 → $130MaintainsOverweightGet Alert
10/26/2023Buy Now117.76%Stifel
Rick Wise63%
$136 → $120MaintainsBuyGet Alert
10/26/2023Buy Now94.17%Wells Fargo
Durgesh Chopra69%
$123 → $107MaintainsEqual-WeightGet Alert
10/26/2023Buy Now115.94%Needham
Mike Matson70%
$140 → $119MaintainsBuyGet Alert
07/27/2023Buy Now163.12%JP Morgan
Robbie Marcus66%
$125 → $145MaintainsOverweightGet Alert
07/27/2023Buy Now154.05%Needham
Mike Matson70%
$139 → $140MaintainsBuyGet Alert
07/27/2023Buy Now155.87%Keybanc
Matthew Mishan53%
$131 → $141MaintainsOverweightGet Alert
07/24/2023Buy Now152.24%Needham
Mike Matson70%
→ $139ReiteratesBuy → BuyGet Alert
06/05/2023Buy Now152.24%Needham
Mike Matson70%
$135 → $139MaintainsBuyGet Alert
05/22/2023Buy Now154.05%CL King
Kristen Stewart52%
→ $140Initiates → BuyGet Alert
04/27/2023Buy Now135.9%Stifel
Rick Wise63%
$118 → $130MaintainsBuyGet Alert
04/27/2023Buy Now132.28%Piper Sandler
Matt O'Brien54%
$118 → $128MaintainsOverweightGet Alert
04/27/2023Buy Now115.94%Wells Fargo
Durgesh Chopra69%
$96 → $119MaintainsEqual-WeightGet Alert
04/27/2023Buy Now144.98%Needham
Mike Matson70%
$122 → $135MaintainsBuyGet Alert
04/27/2023Buy Now137.72%Keybanc
Matthew Mishan53%
$124 → $131MaintainsOverweightGet Alert
03/27/2023Buy Now125.02%Keybanc
Matthew Mishan53%
→ $124UpgradeSector Weight → OverweightGet Alert
02/03/2023Buy Now114.13%Piper Sandler
Matt O'Brien54%
$108 → $118MaintainsOverweightGet Alert
02/03/2023Buy Now121.39%Needham
Mike Matson70%
$106 → $122MaintainsBuyGet Alert
11/15/2022Buy Now92.35%Needham
Mike Matson70%
$90 → $106MaintainsBuyGet Alert
10/14/2022Buy Now63.32%Needham
Mike Matson70%
$123 → $90MaintainsBuyGet Alert
10/12/2022Buy Now54.25%Jefferies
Matthew Taylor72%
→ $85Initiates → HoldGet Alert
08/02/2022Buy Now123.2%Needham
Mike Matson70%
$127 → $123MaintainsBuyGet Alert
07/28/2022Buy Now114.13%Piper Sandler
Matt O'Brien54%
$160 → $118MaintainsOverweightGet Alert
07/28/2022Buy Now130.46%Needham
Mike Matson70%
$155 → $127MaintainsBuyGet Alert
06/23/2022Buy Now99.61%Stifel
Rick Wise63%
$160 → $110MaintainsBuyGet Alert

FAQ

Q

What is the target price for Conmed (CNMD) stock?

A

The latest price target for Conmed (NYSE:CNMD) was reported by Needham on June 12, 2025. The analyst firm set a price target for $61.00 expecting CNMD to rise to within 12 months (a possible 10.69% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Conmed (CNMD)?

A

The latest analyst rating for Conmed (NYSE:CNMD) was provided by Needham, and Conmed downgraded their hold rating.

Q

When was the last upgrade for Conmed (CNMD)?

A

The last upgrade for Conmed Corp happened on March 27, 2023 when Keybanc raised their price target to $124. Keybanc previously had a sector weight for Conmed Corp.

Q

When was the last downgrade for Conmed (CNMD)?

A

The last downgrade for Conmed Corp happened on June 12, 2025 when Needham changed their price target from $61 to $61 for Conmed Corp.

Q

When is the next analyst rating going to be posted or updated for Conmed (CNMD)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Conmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Conmed was filed on June 12, 2025 so you should expect the next rating to be made available sometime around June 12, 2026.

Q

Is the Analyst Rating Conmed (CNMD) correct?

A

While ratings are subjective and will change, the latest Conmed (CNMD) rating was a downgraded with a price target of $61.00 to $61.00. The current price Conmed (CNMD) is trading at is $55.11, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch